4:01 PM
 | 
Nov 21, 2018
 |  BC Extra  |  Company News

NICE recommends Keytruda combo in first-line NSCLC

U.K.’s NICE recommended in draft guidance anti-PD-1 mAb Keytruda pembrolizumab from Merck & Co. Inc. (NYSE:MRK) for use in combination with chemotherapy through the Cancer Drug Fund for untreated, metastatic non-squamous non-small cell lung...

Read the full 149 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >